Search

everythinglearnresearchcommunity

for

Search:↓

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

People are using topical melatonin for diffuse thinning and retrograde alopecia. They are discussing the best brands and application methods.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.

A 26-year-old man who had a hair transplant and used minoxidil with good results is now experiencing shedding and considering finasteride. He's concerned about high progesterone and mild erectile dysfunction before starting the treatment.

The conversation discusses a person successfully using a combination of Minoxidil, finasteride, and other treatments for hair loss, resulting in significantly improved hair. Despite some criticism, many admire his dedication to health and anti-aging research.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.

A user experienced severe scalp itching with MPB and found Nizoral ineffective. A doctor diagnosed seborrheic eczema and prescribed Betacap, which relieved the itching.

The conversation discusses personal experiences with hair loss and highlights the potential impact of anemia and nutrient deficiencies on hair health. Treatments mentioned include changing shampoo/conditioner, taking MSM, collagen, hyaluronic acid, astaxanthin, B12, folate, and bovine blood capsules.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The user got blood work to check hormone levels before starting Finasteride for hair loss and is seeking advice on interpreting the results. They are considering hormone levels in relation to potential side effects of Finasteride.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The conversation is about creating a DIY topical finasteride solution using ethyl alcohol and propylene glycol. A user suggests using a compounding pharmacy instead.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

A 27-year-old male using Minoxidil, Finasteride, and dermarolling for hair loss shared blood test results and experienced side effects with Finasteride. Adjusting the Finasteride dosage helped reduce side effects.

The user is switching from oral to DIY topical finasteride due to side effects and is using a solution with 10 mg finasteride in a 100 mL mixture. They are concerned about the effectiveness of the formula due to white sediment forming in the solution.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

A 20-year-old is concerned about hairline changes and wonders if it's maturing or male pattern baldness (MPB). Suggestions include consulting a specialist and considering treatments like finasteride or minoxidil.

The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

A user seeks advice on using hair fibers for a TV appearance to cover hair loss. Suggestions include practicing application, using a fixing spray, and ensuring color match.

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.